Literature DB >> 15356379

The very low-density lipoprotein (VLDL) receptor: characterization and functions as a peripheral lipoprotein receptor.

Sadao Takahashi1, Juro Sakai, Takahiro Fujino, Hiroaki Hattori, Yasuo Zenimaru, Jinya Suzuki, Isamu Miyamori, Tokuo T Yamamoto.   

Abstract

The very low-density lipoprotein (VLDL) receptor is a member of the low-density lipoprotein (LDL) receptor family. In vitro and in vivo studies have shown that VLDL receptor binds triglyceride (TG)-rich lipoproteins but not LDL, and functions as a peripheral remnant lipoprotein receptor. VLDL receptor is expressed abundantly in fatty acid-active tissues (heart, skeletal muscle and fat), the brain and macrophages. It is likely that VLDL receptor functions in concert with lipoprotein lipase (LPL), which hydrolyses TG in VLDL and chylomicron. In contrast to the LDL receptor, VLDL receptor binds apolipoprotein (apo) E2/2 VLDL particles as well as apoE3/3 VLDL, and the expression is not down-regulated by intracellular lipoproteins. Recently, various functions of the VLDL receptor have been reported in lipoprotein metabolism, metabolic syndrome/atherosclerosis, cardiac fatty acid metabolism, neuronal migration and angiogenesis/tumor growth. Gene therapy of VLDL receptor into the liver showed a benefit effect for lipoprotein metabolism in both LDL receptor knockout and apoE mutant mice. Beyond its function as a peripheral lipoprotein receptor, possibilities of its physiological function have been extended to include signal transduction, angiogenesis and tumor growth.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356379     DOI: 10.5551/jat.11.200

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  37 in total

1.  Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease.

Authors:  Edward K Duran; Aaron W Aday; Nancy R Cook; Julie E Buring; Paul M Ridker; Aruna D Pradhan
Journal:  J Am Coll Cardiol       Date:  2020-05-05       Impact factor: 24.094

2.  Influence of Fatty Acid Modification on Uptake of Lovastatin-Loaded Reconstituted High Density Lipoprotein by Foam Cells.

Authors:  Yun Yang; Ji Wang; Hongliang He; Wenli Zhang; Yuansheng Zhang; Jianping Liu
Journal:  Pharm Res       Date:  2018-05-07       Impact factor: 4.200

3.  Aggressive very low-density lipoprotein (VLDL) and LDL lowering by gene transfer of the VLDL receptor combined with a low-fat diet regimen induces regression and reduces macrophage content in advanced atherosclerotic lesions in LDL receptor-deficient mice.

Authors:  Erin D MacDougall; Farah Kramer; Patti Polinsky; Shelley Barnhart; Bardia Askari; Fredrik Johansson; Rebecca Varon; Michael E Rosenfeld; Kazuhiro Oka; Lawrence Chan; Stephen M Schwartz; Karin E Bornfeldt
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

4.  Homozygous deletion of the very low density lipoprotein receptor gene causes autosomal recessive cerebellar hypoplasia with cerebral gyral simplification.

Authors:  Kym M Boycott; Shauna Flavelle; Alexandre Bureau; Hannah C Glass; T Mary Fujiwara; Elaine Wirrell; Krista Davey; Albert E Chudley; James N Scott; D Ross McLeod; Jillian S Parboosingh
Journal:  Am J Hum Genet       Date:  2005-07-22       Impact factor: 11.025

5.  Anti-VLDL receptor monoclonal antibodies inhibit fibrin-VLDL receptor interaction and reduce fibrin-dependent leukocyte transmigration.

Authors:  Sergiy Yakovlev; Alexey M Belkin; Ling Chen; Chunzhang Cao; Li Zhang; Dudley K Strickland; Leonid Medved
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

Review 6.  Milk lipid regulation at the maternal-offspring interface.

Authors:  Dengbao Yang; HoangDinh Huynh; Yihong Wan
Journal:  Semin Cell Dev Biol       Date:  2017-10-24       Impact factor: 7.727

7.  Interaction of Fibrin with the Very Low Density Lipoprotein Receptor: Further Characterization and Localization of the Fibrin-Binding Site.

Authors:  Sergiy Yakovlev; Leonid Medved
Journal:  Biochemistry       Date:  2015-07-21       Impact factor: 3.162

8.  Normalization and improvement of CNS deficits in mice with Hurler syndrome after long-term peripheral delivery of BBB-targeted iduronidase.

Authors:  Salim S El-Amouri; Mei Dai; Jing-Fen Han; Roscoe O Brady; Dao Pan
Journal:  Mol Ther       Date:  2014-08-04       Impact factor: 11.454

9.  NADPH oxidase 2 plays a critical role in dysfunction and apoptosis of pancreatic β-cells induced by very low-density lipoprotein.

Authors:  Juan Jiao; Lin Dou; Miao Li; Yonggang Lu; Han-Bang Guo; Yong Man; Shu Wang; Jian Li
Journal:  Mol Cell Biochem       Date:  2012-08-22       Impact factor: 3.396

10.  A neuronal VLDLR variant lacking the third complement-type repeat exhibits high capacity binding of apoE containing lipoproteins.

Authors:  Keiko Sakai; Oliver Tiebel; M Cecilia Ljungberg; Merry Sullivan; Hye-Jeong Lee; Tomoya Terashima; Rongying Li; Kunihisa Kobayashi; Hui-Chen Lu; Lawrence Chan; Kazuhiro Oka
Journal:  Brain Res       Date:  2009-04-22       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.